Clinical Study to Investigate the PK, Efficacy, and Safety of Wilate in Patients With Severe Hemophilia A
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02954575 |
Recruitment Status :
Completed
First Posted : November 3, 2016
Results First Posted : December 3, 2019
Last Update Posted : January 19, 2021
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Severe Hemophilia A | Drug: Wilate | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 57 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Wilate in Previously Treated Patients With Severe Hemophilia A |
Actual Study Start Date : | December 2016 |
Actual Primary Completion Date : | March 29, 2018 |
Actual Study Completion Date : | March 29, 2018 |

Arm | Intervention/treatment |
---|---|
Experimental: All patients
All patients will receive Wilate for prophylactic treatment
|
Drug: Wilate
Other Name: von Willebrand factor / Factor VIII (plasma derived) |
- Total Annualized Bleeding Rate (TABR) [ Time Frame: 6 months ]The total number of bleeding events (BEs) was documented by patients in a patient diary (together with the investigator in case of on-site treatments), which was reviewed at each follow-up visit by site personnel.
- Spontaneous Annualized Bleeding Rate (SABR) [ Time Frame: 6 months ]The number of spontaneous bleeding events (BEs) was documented by patients in a patient diary (together with the investigator in case of on-site treatments), which was reviewed at each follow-up visit by site personnel.
- Efficacy of Wilate in the Treatment of Breakthrough BEs [ Time Frame: 6 months ]The proportion of BEs successfully treated with Wilate were documented by the patient (together with the investigator in case of on-site treatments) in the patient diary for all BEs according to a 4-point hemostatic efficacy scale including the four items: 'excellent,' 'good,' moderate,' and 'none', where 'excellent' was defined as "Abrupt pain relief and/or unequivocal improvement in objective signs of bleeding within approximately 8 hours after a single injection" (best outcome) and 'none' was defined as "No improvement within 12 hours, or worsening of symptoms, requiring more than two injections for complete resolution" (worst outcome). All efficacy ratings assessed as either 'excellent' or 'good' were considered 'successfully treated.'
- Wilate Consumption Data (Average Total Normdose of FVIII IU/kg Per Month of Study) for Prophylaxis [ Time Frame: 6 months ]The average consumption of Wilate per month of study (IU/kg) for all patients receiving prophylaxis.
- Pharmacokinetic (PK) Assessment (Area Under the Curve [AUC] Norm) of FVIII:C [ Time Frame: Initial PK visit (Day -1) and PK study completion visit (6 months); data collected 1 h prior to injection and 15 min, 1 h, 3 h, 6 h, 9 h, 24 h, 30 h and 48 h after the end of injection ]PK assessments of FVIII:C were conducted using the one-stage (OS) assay. The value of the AUCnorm of FVIII:C was calculated based on the FVIII:C values measured in the patients participating in the PK study.
- Pharmacokinetic (PK) Assessment (in Vivo Half-Life (t1/2)) of FVIII:C [ Time Frame: Initial PK assessment (Day -1) and PK study completion visit (6 months); data collected 1 h prior to infusion and 15 min, 1 h, 3 h, 6 h, 9 h, 24 h, 30 h and 48 h after the end of injection ]PK assessments of FVIII:C were conducted using the one-stage (OS) assay. The in vivo half-life of FVIII:C was calculated based on the FVIII:C values measured in the patients participating in the PK study.
- Pharmacokinetic (PK) Assessment (Maximum Plasma Concentration [Cmax]) of FVIII:C [ Time Frame: Initial PK assessment (Day -1) and 6 months ]PK assessments of FVIII:C were conducted using the one-stage (OS) assay. The maximum plasma concentration of FVIII:C was calculated based on the FVIII:C values measured in the patients participating in the PK study.
- Incremental in Vivo Recovery (IVR) of Wilate Over Time [ Time Frame: Baseline, 3 and 6 months ]The rise in FVIII activity in IU/dl per unit dose administered in IU/kg was determined from all patients at baseline, 3 and 6 months, using the OS assay.
- Association Between ABO Blood Type and the FVIII:C Half-life of Wilate (OS Assay) [ Time Frame: 6 months ]Analysis of variance (ANOVA) was used in an exploratory sense to assess an association between ABO blood type and the FVIII:C half-life of Wilate. This was analyzed by calculating the mean square in a one-stage assay.
- Association Between VWF:Ag Concentration and the FVIII:C Half-life of Wilate [ Time Frame: 6 months ]ANOVA was used in an exploratory sense to assess an association between VWF:Ag with the FVIII:C half-life of Wilate. This was analyzed by calculating the mean square in a one-stage assay.
- Safety and Tolerability of Wilate by Monitoring Adverse Events (AEs) Throughout the Study [ Time Frame: 6 months ]At each (scheduled or unscheduled) study visit, AEs were documented by the investigator throughout the study.
- Immunogenicity of Wilate by Testing for FVIII Inhibitors [ Time Frame: 6 months ]FVIII inhibitor activity was determined at each study visit before the injection of Wilate using the modified Bethesda assay (Nijmegen modification).
- Virus Safety Measured by the Number of Parvovirus B19 Seroconversions Between Baseline (BL) and End of Study [ Time Frame: 6 months ]Virus safety was evaluated by taking a plasma sample for parvovirus B19 antibody testing before the first injection of Wilate. All patients negative at screening were tested again at the study completion visit. The number with Parvovirus B19 seroconversions between BL and end of study was recorded.
- Efficacy of Wilate in Surgical Prophylaxis [ Time Frame: 6 months ]Hemostatic efficacy was assessed at the end of surgery by the surgeon and at end of the postoperative period by the hematologist, using a 4-point hemostatic efficacy scale including the four items: 'excellent' (best possible outcome), 'good', 'moderate' and 'none' (worst outcome). Overall efficacy was assessed by the investigator, taking both the intra and postoperative assessments into account, and using the 'excellent,' 'good,' moderate,' and 'none' scale.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 12 Years and older (Child, Adult, Older Adult) |
Sexes Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Severe hemophilia A (<1% FVIII:C) according to medical history
- Male patients aged ≥12 years
- Previous treatment with a FVIII concentrate for at least 150 exposure days (EDs)
- Immunocompetence (CD4+ count >200/µL)
- Good documentation of the historical bleeding rate (at least for the 6 months preceding study start)
- Voluntarily given, fully informed written and signed consent obtained by the patient (or parent/legal guardian in case of adolescents) before any study-related procedures are conducted
Whenever possible, the interval between the Screening Visit and the PK or Non-PK Visit should not exceed 30 days. If the 30-day interval is exceeded, determination of the CD4+ count is to be repeated and must be >200/µL for patients to be enrolled (i.e., exclusion criterion no. 4).
Exclusion Criteria:
- Any coagulation disorders other than hemophilia A
- History of FVIII inhibitor activity (≥0.6 BU) or detectable FVIII inhibitory anti-bodies (≥0.6 BU using the Nijmegen modification of the Bethesda assay) at screening, as determined by the central laboratory
- Severe liver or kidney diseases (alanine aminotransferase [ALAT] and aspartate transaminase [ASAT] levels >5 times of upper limit of normal, creatinine>120 µmol/L)
- Patients receiving or scheduled to receive immunomodulating drugs (other than anti-retroviral chemotherapy) such as alpha-interferon, prednisone (equivalent to >10 mg/day), or similar drugs
- Treatment with any investigational medicinal product in another interventional clinical study currently or within 4 weeks before enrollment

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02954575
Bulgaria | |
Specialized Hospital for Active Treatment "Joan Pavel" | |
Sofia, Bulgaria | |
Hungary | |
National Haemophilia Centre | |
Budapest, Hungary | |
Poland | |
Krakowskie Centrum Medyczne | |
Krakow, Poland | |
Korczowski Bartosz Gabinet Lekarski | |
Rzeszow, Poland | |
Romania | |
Centrul Medical Unirea -Policlinica Enescu | |
Bucharest, Romania | |
Russian Federation | |
Barnaul Branch of RAMS hematology center | |
Barnaul, Russian Federation | |
Federal Scientific Hematology Center | |
Moscow, Russian Federation |
Study Director: | Cristina Solomon, MD | Octapharma |
Documents provided by Octapharma:
Responsible Party: | Octapharma |
ClinicalTrials.gov Identifier: | NCT02954575 |
Other Study ID Numbers: |
WIL-27 |
First Posted: | November 3, 2016 Key Record Dates |
Results First Posted: | December 3, 2019 |
Last Update Posted: | January 19, 2021 |
Last Verified: | December 2020 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Hemophilia A Blood Coagulation Disorders, Inherited Blood Coagulation Disorders Hematologic Diseases Coagulation Protein Disorders |
Hemorrhagic Disorders Genetic Diseases, Inborn Factor VIII Coagulants |